Xeris Biopharma Holdings Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Xeris Biopharma Holdings Inc 's ROA in the second quarter of 2026?
Xeris Biopharma Holdings Inc recorded a cumulative net loss of $-14 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -3.41%.

However, within the Healthcare sector Xeris Biopharma Holdings Inc achieved the highest return on assets. While the total ranking for ROA unchanged, relative to the first quarter of 2026 at no. .

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	59.45 %	24.27 %	26.16 %	22.62 %	7.49 %
Y / Y Net Income Change	-	-	-	-62.64 %	-
Net Income (TTM) in million	-14	13	-10	-21	-19
Return On Assets (TTM)	-3.41 %	3.49 %	-2.84 %	-6.36 %	-6.04 %
XERS's Total Ranking	#	#	#	#	#
Total Assets (TTM) in million	534	392	384	370	335
Seq. Total Assets Change	36.13 %	2.21 %	3.6 %	10.61 %	6.1 %
Seq. Net Income Change	-	-59.68 %	792.19 %	-	-

XERS's 5 Years Annual ROA >> Back to XERS Management Effectiveness >> Compare XERS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Assets Statistics
High	Average	Low
0 %	0 %	0 %

Financial Statements
Xeris Biopharma Holdings Inc 's Assets	$ 534 million	XERS's Balance sheet
Xeris Biopharma Holdings Inc 's Income	$ -31 million	Quarterly XERS's Income Statement
XERS's Income by Division		See XERS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	26.16 %	0.71 %	-12.2 %	12.96 %	91.24 %
Total Assets in million	384	304	302	344	304
Y / Y Net Income Change	-51.15 %	81.59 %	-12.29 %	-	-
Net Income in million	1	2	1	1	-245
Annual Return On Assets	0.29 %	0.75 %	0.41 %	0.41 %	-80.64 %

XERS's 5 Years Annual ROA >> Back to XERS Management Effectiveness >> Compare XERS ROA to its Competitors

Comment on XERS's ROA in the fiscal year ending 2025

In the fiscal year 2025 Xeris Biopharma Holdings Inc 's ROA decreased compared to previous year to 0.29 %, due to deterioration of net income -51.15 % to $1.11 million, from $2.27 million a year ago, as XERS's assets were $383.53 million.

More Return On Assets Ratios
XERS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
XERS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for XERS's Competitors
Subscribers only: Roa for Xeris Biopharma Holdings Inc 's Suppliers
Subscribers only: Return On Assets for XERS's Customers

You may also want to know
XERS's Roi	XERS's Inventory Turnover Ratio	XERS's Growth Rates	XERS's Dividend Comparisons
	XERS's Profitability Ratios	XERS's Asset Turnover Ratio	XERS's Dividend Growth
XERS's Roe	XERS's Valuation Ratios	XERS's Financial Strength Ratios	XERS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:40:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.